Clinic
Holy Cross Hospital INC
Holy Cross Hospital INC was paid $7.89M by Medicaid between Jan 2018 and Dec 2024, across 272 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoHOLY CROSS HOSPITAL INC
FT LAUDERDALE, FL 33308
FT LAUDERDALE, FL 33308
33aNPI1639197395assigned 07/18/2006
33bProvider typeRadiology Clinic/Center
28Total paid$7.89M
24GClaims538,345
24DCodes billed272
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiology Clinic/Center providers in Florida
Rank by total paid#3 of 43
Median peer was paid$36K
This provider vs. median221×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,606 | $302K | |
| 2019 | 92,022 | $777K | |
| 2020 | 91,336 | $872K | |
| 2021 | 127,330 | $2.07M | |
| 2022 | 123,573 | $2.13M | |
| 2023 | 45,675 | $1.24M | |
| 2024incomplete | 12,803 | $501K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 21,901 | 17,933 | $1.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 9,183 | 8,170 | $864K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.9% | 46,255 | 27,243 | $779K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 13,052 | 10,095 | $683K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.3% | 6,378 | 5,579 | $577K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 6,676 | 5,016 | $304K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 3,762 | 3,289 | $261K |
| 36415 | Collection of venous blood by venipuncture | 2.7% | 30,270 | 19,248 | $214K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 10,212 | 7,151 | $192K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 2,699 | 1,925 | $148K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 8,797 | 1,527 | $140K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 1,700 | 1,309 | $121K |
260 more codes
| 80053 | Comprehensive metabolic panel | 1.5% | 23,134 | $119K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 1.5% | 1,400 | $117K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 6,651 | $115K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 6,408 | $111K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 10,135 | $106K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 7,748 | $87K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,698 | $84K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.0% | 1,026 | $82K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 824 | $67K |
| A9270 | Non-covered item or service | <1% | 25,527 | $60K |
| G0378 | Hospital observation service, per hour | <1% | 5,741 | $53K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,137 | $51K |
| 11043 | <1% | 505 | $51K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,340 | $40K |
| 86900 | <1% | 2,869 | $38K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,831 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 430 | $35K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 528 | $34K |
| 87015 | <1% | 1,337 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,974 | $32K |
| 81025 | <1% | 3,680 | $31K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 624 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,921 | $31K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,037 | $30K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 238 | $30K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 520 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,465 | $27K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 704 | $26K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 466 | $25K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 275 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,521 | $21K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,090 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,064 | $19K |
| 81001 | <1% | 11,634 | $18K | |
| 81003 | <1% | 4,482 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,686 | $17K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 182 | $16K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 418 | $16K |
| 87631 | <1% | 619 | $14K | |
| 76641 | <1% | 284 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,465 | $14K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,850 | $14K |
| 87077 | <1% | 2,747 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,011 | $11K |
| 76801 | <1% | 548 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 858 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,493 | $10K |
| 76830 | Ultrasound, transvaginal | <1% | 426 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,739 | $9K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 20 | $8K |
| 97161 | <1% | 818 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,171 | $7K |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 108 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 367 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,619 | $7K |
| 87070 | <1% | 1,805 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 757 | $6K |
| 85610 | <1% | 5,478 | $6K | |
| 87186 | <1% | 2,209 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 684 | $6K |
| 20610 | <1% | 853 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 150 | $5K |
| 81513 | <1% | 214 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,014 | $5K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,119 | $5K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,518 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,248 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 352 | $5K |
| 73030 | <1% | 722 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 378 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,614 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 442 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 669 | $4K |
| 85730 | <1% | 4,135 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 152 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,286 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 684 | $4K |
| 73630 | <1% | 442 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 529 | $4K |
| 90698 | <1% | 154 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 738 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,041 | $3K |
| 99499 | <1% | 36 | $3K | |
| 73610 | <1% | 186 | $3K | |
| 87799 | <1% | 99 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 240 | $3K |
| 0002A | <1% | 404 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 25 | $3K |
| 86850 | <1% | 1,914 | $3K | |
| 84484 | <1% | 5,620 | $3K | |
| 0001A | <1% | 415 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,414 | $3K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 174 | $3K |
| 90647 | <1% | 81 | $3K | |
| 90670 | <1% | 393 | $3K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 438 | $3K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 725 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,481 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,892 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 19 | $2K |
| 80061 | Lipid panel | <1% | 4,339 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 141 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,201 | $2K |
| 88142 | <1% | 698 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 54 | $2K |
| 84702 | <1% | 1,891 | $2K | |
| 87205 | <1% | 1,249 | $2K | |
| 87040 | <1% | 2,235 | $2K | |
| 87210 | <1% | 490 | $2K | |
| 87634 | <1% | 246 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 225 | $2K |
| 94060 | <1% | 33 | $2K | |
| 83735 | <1% | 6,309 | $2K | |
| 87088 | <1% | 2,012 | $2K | |
| 90686 | <1% | 357 | $2K | |
| 97162 | <1% | 103 | $2K | |
| 86901 | <1% | 2,869 | $2K | |
| 73564 | <1% | 110 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,760 | $2K |
| 73502 | <1% | 311 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 29 | $1K |
| 90633 | <1% | 130 | $1K | |
| C1769 | Guide wire | <1% | 221 | $1K |
| 93971 | <1% | 139 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,803 | $1K |
| 82728 | <1% | 921 | $1K | |
| 82550 | <1% | 373 | $1K | |
| 87481 | <1% | 415 | $1K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 163 | $1K |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 386 | $1K |
| 73562 | <1% | 162 | $1K | |
| 36416 | <1% | 384 | $1K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 67 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,406 | $1K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 30 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 22 | $992.20 |
| 82607 | <1% | 1,143 | $979.51 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 47 | $922.20 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 801 | $888.08 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 784 | $880.49 |
| 83690 | <1% | 4,261 | $880.23 | |
| 90715 | <1% | 246 | $878.18 | |
| 72170 | <1% | 240 | $841.33 | |
| 87522 | Neg quan hep c or qual rna | <1% | 54 | $813.26 |
| 84439 | <1% | 1,066 | $810.76 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,347 | $810.23 |
| 85027 | <1% | 1,904 | $769.29 | |
| 77080 | <1% | 91 | $768.83 | |
| 90680 | <1% | 149 | $765.91 | |
| 86140 | <1% | 881 | $734.59 | |
| 59025 | Fetal non-stress test | <1% | 390 | $719.98 |
| 73130 | <1% | 163 | $704.56 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 34 | $652.72 |
| 84100 | <1% | 2,486 | $646.97 | |
| 83605 | <1% | 1,932 | $608.55 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 97 | $599.73 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 38 | $585.41 |
| 84703 | <1% | 96 | $558.20 | |
| 72100 | <1% | 117 | $550.85 | |
| 82105 | <1% | 120 | $528.68 | |
| 90685 | <1% | 71 | $514.35 | |
| 84466 | <1% | 824 | $458.06 | |
| 82043 | <1% | 574 | $455.96 | |
| 80184 | <1% | 423 | $451.82 | |
| 99000 | <1% | 75 | $426.35 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 825 | $421.53 |
| 96417 | <1% | 84 | $419.19 | |
| 90734 | <1% | 26 | $410.27 | |
| 83540 | <1% | 920 | $408.13 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 636 | $407.91 |
| 82570 | <1% | 927 | $406.91 | |
| 90696 | <1% | 34 | $397.35 | |
| 87075 | <1% | 221 | $384.38 | |
| 83880 | <1% | 952 | $370.48 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 269 | $348.28 |
| 71250 | <1% | 20 | $337.20 | |
| 97116 | <1% | 105 | $327.46 | |
| 80076 | <1% | 1,228 | $303.29 | |
| 82746 | <1% | 451 | $297.33 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 100 | $291.22 |
| 85652 | <1% | 810 | $270.11 | |
| 90744 | <1% | 104 | $269.19 | |
| 86592 | <1% | 685 | $261.23 | |
| 90723 | <1% | 19 | $254.88 | |
| 86762 | <1% | 85 | $236.82 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 22 | $201.55 |
| 90474 | <1% | 210 | $197.92 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 207 | $195.20 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 82 | $184.96 |
| 93017 | <1% | 14 | $182.02 | |
| 84153 | <1% | 142 | $181.56 | |
| 93296 | <1% | 39 | $174.75 | |
| 82805 | <1% | 23 | $171.49 | |
| 74018 | <1% | 13 | $166.71 | |
| 90710 | <1% | 45 | $160.20 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 191 | $148.30 |
| 97165 | <1% | 156 | $147.54 | |
| 87340 | <1% | 518 | $140.17 | |
| 86803 | <1% | 660 | $127.71 | |
| 90756 | <1% | 138 | $123.66 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 667 | $111.94 |
| 90688 | <1% | 80 | $109.83 | |
| 85007 | <1% | 300 | $108.62 | |
| 83970 | <1% | 141 | $107.70 | |
| 82272 | <1% | 40 | $87.89 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 744 | $86.56 |
| 46600 | <1% | 13 | $68.28 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 32 | $62.75 |
| 87512 | <1% | 46 | $61.81 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 17 | $60.65 |
| 80050 | General health panel | <1% | 33 | $58.74 |
| 83615 | <1% | 39 | $56.58 | |
| 84403 | <1% | 14 | $36.84 | |
| 94729 | <1% | 33 | $33.43 | |
| 94726 | <1% | 35 | $32.86 | |
| 0012A | <1% | 158 | $32.51 | |
| 88342 | <1% | 78 | $25.95 | |
| 85379 | <1% | 28 | $23.34 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 52 | $22.23 |
| 82950 | <1% | 128 | $15.75 | |
| 84550 | <1% | 106 | $15.52 | |
| 86780 | <1% | 35 | $12.65 | |
| 84146 | <1% | 29 | $11.52 | |
| 81000 | <1% | 49 | $11.31 | |
| 82248 | <1% | 91 | $9.39 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 630 | $8.81 |
| 80375 | <1% | 65 | $7.79 | |
| 82610 | <1% | 21 | $6.62 | |
| 51798 | <1% | 19 | $5.35 | |
| 86360 | <1% | 22 | $4.44 | |
| 0011A | <1% | 158 | $4.08 | |
| 87046 | <1% | 24 | $2.59 | |
| 87045 | <1% | 24 | $2.59 | |
| 96376 | 0% | 914 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 466 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 38 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 30 | $0.00 |
| 86704 | 0% | 20 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 46 | $0.00 |
| 90674 | 0% | 14 | $0.00 | |
| 86593 | 0% | 34 | $0.00 | |
| 86317 | 0% | 23 | $0.00 | |
| 87536 | 0% | 22 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 19 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 20 | $0.00 |
| 82378 | 0% | 40 | $0.00 | |
| 87905 | 0% | 301 | $0.00 | |
| 0003A | 0% | 61 | $0.00 | |
| 81329 | 0% | 20 | $0.00 | |
| 99001 | 0% | 14 | $0.00 | |
| 81243 | 0% | 20 | $0.00 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 98 | $0.00 |
| 83020 | 0% | 59 | $0.00 | |
| 73110 | 0% | 101 | $0.00 | |
| 83721 | 0% | 20 | $0.00 | |
| 99152 | 0% | 21 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 28 | $0.00 |
| 77066 | Tomosynthesis, mammo | 0% | 19 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMONICE, PIERRE (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Holy Cross Hospital INC | Ft. Lauderdale, FL | $1.60M |
| Holy Cross Senior Services INC | Fort Lauderdale, FL | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.